UroGen Pharma Ltd. (URGN) Stock Price & How to Invest

Last updated November 2026

Short answer

URGN is UroGen Pharma, an Israeli-incorporated, Princeton-based biotech whose non-surgical bladder cancer drugs Jelmyto and Zusduri are both FDA approved and selling, and whose stock is now a launch-execution story rather than a binary clinical bet. Revenue more than tripled year over year in the September 2026 quarter to ~$89.0M on the Zusduri ramp, and the company posted its first meaningful operating profit, but the quarter missed earnings estimates and Jelmyto guidance was cut. At about $31.68 on November 20, 2026 (up about 40% year to date, down about 32% over three months) the shares trade around ~6x trailing sales.

URGN stock price

As of 2026-11-20, UroGen Pharma Ltd. (URGN) last closed at $27.65, up 6.9% over the past year. Over the past 52 weeks it has traded between $17.00 and $50.29.

URGN last close
$27.65
1 day
-12.86%
1 month
-22.07%
1 year
+6.88%
52-week range
$17.00 to $50.29
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or UroGen Pharma Ltd.'s investor relations page. Walnut is informational, not investment advice.

URGN key stats

At $27.65 on November 20, 2026, UroGen Pharma Ltd. (URGN) has a market cap of $1.4B.

Market cap
$1.4B
P/E (forward)
11.1
Beta
1.64

Market cap, P/E and yield are measured at the $27.65 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with UroGen Pharma Ltd. (URGN)?

The last two weeks for UroGen Pharma Ltd., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • URGN closed at $27.65 on November 20, 2026, up 5.6% over the past five trading days (from $26.18).

UroGen Pharma Ltd. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does UroGen Pharma Ltd. (URGN) do?

UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on whose NDA the FDA accepted in October 2026, with a June 14, 2027 PDUFA target date), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus that dosed its first Phase 1 patient in November 2026. The company has about 300 employees and is run by CEO Liz Barrett.

The investment picture changed shape over the past year. Third-quarter 2026 revenue was ~$89.0M against ~$27.5M a year earlier, with Zusduri contributing ~$68.0M, up ~35% sequentially, and the company posted operating income of ~$8.3M, up from ~$0.1M in the June quarter, while keeping full-year operating expense guidance at ~$260M to $270M, toward the upper end. Gross margin ran about 91.6%, which is what makes the operating leverage credible if the ramp holds. Net loss narrowed to ~$1.5M ($0.03 per share), but analysts had expected a profit of about $0.11, and the company cut 2026 Jelmyto guidance to about $90M from ~$97M to $101M; the shares fell on the results. The balance sheet is the counterweight: ~$90.5M of cash and marketable securities against ~$196M of debt and a prepaid forward obligation owed to RTW on future product sales, leaving a shareholders' deficit of ~$125M. The stock nearly tripled off its October 2025 low to about $47 and a ~$2.3B market cap in August 2026, then gave back part of that move, closing near $31.68 on November 20, 2026 (a ~$1.55B market cap, up about 40% year to date and about 28% over one year). What is being priced is still Zusduri becoming a large franchise, not what it has already sold.

In August 2026 UroGen also widened its pipeline beyond RTGel, agreeing to invest up to $7M ($4M of it invested in the third quarter) in IntraGel Therapeutics in exchange for a research license to IntraGel's biodegradable SRGel sustained-release platform, options on up to three oncology products built on it, and an option on TumoCure, an intratumoral cisplatin gel for advanced head and neck cancer, after a Phase 2 study.

What's driving UroGen Pharma Ltd. (URGN)?

1. The Zusduri launch curve

Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second and ~$68.0M in the third, and the underlying adoption metrics moved with it: 1,538 activated sites of care at September 30 (up from 1,444), 662 unique prescribers (up from 452), and 331 repeat prescribers, or about 50% of prescribers, up from 45% a quarter earlier. Repeat use is the number that matters most, because it separates trial of a new product from a change in practice. Sequential growth slowed from ~73% to ~35%, which is the expected shape of a launch curve but is also what the market reacted to. Management has not guided full-year Zusduri revenue. For the December quarter, analysts expect total revenue of about $107M and EPS of about $0.39, which would be the first quarterly net profit.

2. Operating leverage arriving faster than expected

The September quarter produced operating income of ~$8.3M on ~91.6% gross margin, against an operating loss of ~$27.4M a year earlier and ~$0.1M of operating income in June. Net loss narrowed to ~$1.5M ($0.03 per share) from ~$33.3M, with the remaining gap driven by ~$4.8M of interest on the Pharmakon term loan and ~$4.5M of non-cash financing expense on the RTW obligation. The result still missed a ~$0.11 EPS estimate because the company is spending the incremental gross profit: R&D rose to ~$26.0M and SG&A to ~$47.2M, and 2026 operating expense guidance of ~$260M to $270M is now expected toward the upper end.

3. Lifecycle extension and patent runway

UGN-103 is a reformulated version of the same mitomycin plus RTGel combination with simpler manufacturing and reconstitution, and showed 94.5% six-month duration of response in the Phase 3 UTOPIA trial against 91.9% for Zusduri in ENVISION. The FDA accepted the NDA in October 2026 with a PDUFA target action date of June 14, 2027, and UroGen plans to submit 12-month duration data during review and to start a roughly 300-patient Phase 3 trial, LONGVIEW-HR, in high-risk disease in the fourth quarter of 2026. A US method-of-treatment patent covering recurrent low-grade intermediate-risk NMIBC has now issued and is expected to run into July 2044, covering both Zusduri and, if approved, UGN-103, which matters because Zusduri's regulatory exclusivity alone expires in June 2028.

4. Jelmyto as the mature base with a dated end

Jelmyto generated ~$21.0M in the September quarter, down from ~$25.7M a year earlier and including a one-time ~$1.5M unfavorable gross-to-net adjustment tied to a CMS discarded-drug true-up. UroGen cut full-year 2026 Jelmyto guidance to about $90M from ~$97M to $101M, citing that adjustment and competitive trial enrollment affecting patient starts, which puts the product slightly below the ~$94M booked in 2025. UroGen settled Teva's ANDA challenge in June 2026 by licensing a generic entry date of September 15, 2030. That converts an open-ended legal risk into a known cliff, which is useful for modelling but does not make the decline go away.

What are the risks to UroGen Pharma Ltd. (URGN)?

The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year, and at-the-market equity capacity makes dilution an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now about three quarters of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and sequential growth already slowed from ~73% to ~35% in the third quarter. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings, competing clinical trials that management says are pulling Jelmyto patient starts, and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent running to 2044 has to hold up to be worth what the market is assigning it. The share price itself has become a risk signal: the stock fell about 32% over the three months to November 20, 2026, from a 52-week high of about $50.81, and dropped after the third-quarter EPS miss, while options implied volatility has been rising.

What is the UroGen Pharma Ltd. (URGN) forecast?

7 analysts publish price targets on URGN, averaging $60.71 as of November 2026, or +119.6% against the $27.65 share price on November 20, 2026. The published targets run from $54.00 to $75.00, a moderate spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full URGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is URGN a buy or a sell?

We give no verdict on UroGen Pharma Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Zusduri launch curve. Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second and ~$68.0M in the third, and the underlying adoption metrics moved with it: 1,538 activated sites of care at September 30 (up from 1,444), 662 unique prescribers (up from 452), and 331 repeat prescribers, or about 50% of prescribers, up from 45% a quarter earlier. The most optimistic published target, $75.00, assumes this works close to its best case.

The case against. The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. The most pessimistic target, $54.00, is roughly what URGN is worth if this bites instead.

Read the full bull and bear case on URGN, including what would have to change to break either one. Walnut is not an investment adviser.

Has UroGen Pharma Ltd. (URGN) split its stock?

No. UroGen Pharma Ltd. (URGN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is UroGen Pharma Ltd. (URGN) valued?

Market cap, P/E and dividend yield at today's price are in the URGN key stats above. The business figures below come from UroGen Pharma Ltd.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$250M (latest quarter up ~224% year over year)
  • Revenue (Q3 2026): ~$89.0M (Zusduri ~$68.0M, Jelmyto ~$21.0M)
  • Net loss (Q3 2026 / TTM): ~$1.5M (~$0.03 per share, vs ~$0.11 profit expected) / ~$66M
  • Gross margin: ~91%
  • Cash & total debt: ~$91M and ~$196M (plus RTW prepaid forward obligation)

As of November 2026: There is no meaningful trailing P/E because UroGen is still loss-making over the last twelve months, roughly ~$66M of net loss, so the shares are framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$1.55B of market value against ~$250M of trailing revenue is roughly 6x sales, and analysts' 2027 estimates (revenue near $535M, EPS near $2.50) put the forward P/E around 13x, which is what the stock is being priced on; the mean analyst target of ~$60.71 from seven analysts sits well above the price. Debt and the RTW obligation still matter here, unlike for a cash-rich clinical-stage biotech, and the next data point is fourth-quarter results in early 2027.

Who competes with UroGen Pharma Ltd. (URGN)?

The incumbent standard of care

Zusduri's real competitor is not another drug, it is transurethral resection of bladder tumor, the surgery UroGen is trying to displace, plus the compounded intravesical chemotherapy regimens such as gemcitabine and docetaxel that urology practices already mix and administer at a fraction of the branded price. Every quarter of Zusduri growth is a quarter of urologists changing a workflow they have used for decades, which is why the repeat-prescriber count is the metric management leads with.

Bladder cancer drug developers

Johnson & Johnson, Merck, ImmunityBio and CG Oncology are all pursuing non-muscle invasive bladder cancer, mostly in the higher-risk and BCG-unresponsive settings rather than UroGen's low-grade intermediate-risk niche. The overlap is indirect today, but these companies are building urology sales forces and site relationships that reach the same physicians, and UroGen's own plan to take UGN-103 into high-risk NMIBC moves it toward them rather than away.

Generic and follow-on entrants

Teva filed an ANDA for a generic Jelmyto and settled with UroGen in June 2026 for a licensed entry date of September 15, 2030. That is the template for how this franchise gets attacked: the active ingredient is mitomycin, an old and cheap generic chemotherapy, and the defensible part is the RTGel delivery formulation and the method patents around it. Any erosion of that formulation protection is what would let low-cost competition in.

What stocks are similar to UroGen Pharma Ltd. (URGN)?

Other names that sit close to URGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in UroGen Pharma Ltd. (URGN)

There are three common ways to get URGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so URGN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where URGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on UroGen Pharma Ltd. (URGN)

UroGen has crossed from clinical-stage biotech into a real commercial franchise, but at roughly $1.55B of market value as of November 2026 against ~$250M of trailing revenue and a shareholders' deficit of ~$125M, the valuation is still underwriting several more quarters of Zusduri growth rather than the current run rate.

More on UroGen Pharma Ltd. (URGN)

Whether URGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is URGN a buy or a sell?, and where the stock could go from here in the URGN stock forecast.

For income investors, whether URGN pays a dividend and how the payout looks is covered in does URGN pay a dividend? And to weigh URGN against a peer, read the full side-by-side comparisons: URGN vs JNJ and URGN vs IBRX.

Wondering how URGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about UroGen Pharma Ltd.

Ask Walnut's AI anything about URGN and see how it fits what you own.

FAQ

What does UroGen Pharma actually sell?

+

Two approved drugs. Jelmyto treats low-grade upper tract urothelial cancer and has been on the market since 2020. Zusduri, approved in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both use UroGen's RTGel hydrogel, which turns from liquid to gel at body temperature so the chemotherapy stays in contact with tumor tissue instead of washing out.

Is URGN profitable?

+

Not yet on a net basis. The September 2026 quarter produced operating income of about $8.3M, up from ~$0.1M in June, but interest on the term loan and non-cash financing expense on the RTW obligation still left a net loss of ~$1.5M ($0.03 per share), short of the ~$0.11 profit analysts expected. Trailing twelve-month net loss is roughly ~$66M, down sharply from the prior year as Zusduri revenue scaled. Analysts expect about $0.39 of EPS in the fourth quarter of 2026, which would be the first positive quarterly EPS.

Why did revenue more than triple year over year?

+

Zusduri. It contributed ~$68.0M in the third quarter of 2026, up ~35% from the second quarter, against only a few months of sales in the year-ago period, since FDA approval came in June 2025. Jelmyto was ~$21.0M and lower than a year earlier. Any trailing-twelve-month figure for UroGen (about $250M) understates the current run rate because it still contains early-launch quarters.

How large could Zusduri get?

+

UroGen estimates the annual treatable US population for low-grade intermediate-risk NMIBC at roughly 82,000 patients and describes the addressable opportunity as potentially over $5B, which is a company estimate rather than an independent one. Management has declined to give full-year 2026 Zusduri revenue guidance, so the near-term evidence is the quarterly sequential growth rate (~35% in the third quarter) and the repeat-prescriber share, which reached about 50% at September 30, 2026.

What happens to Jelmyto when the generic arrives?

+

UroGen settled Teva's patent challenge in June 2026 by granting a license for generic Jelmyto to launch on September 15, 2030, if approved. Jelmyto is now guided to about $90M for 2026, cut from ~$97M to $101M after a one-time gross-to-net adjustment and competing trial enrollment, so the franchise is already a mature and slightly shrinking base. The settlement fixes the date rather than removing the eventual erosion.

How much debt does UroGen carry?

+

As of September 30, 2026 Yahoo Finance data showed ~$196M of total debt under a Pharmakon senior secured facility, refinanced in early 2026 with $75M of additional borrowings, plus a prepaid forward obligation to RTW that is repaid out of future Jelmyto and Zusduri sales. Total liabilities of ~$397M against ~$272M of assets produce a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities.

Does URGN pay a dividend?

+

No. UroGen has never paid a dividend and states it does not anticipate doing so in the foreseeable future. The company is still funding a commercial launch and a clinical pipeline, and its loan agreement is a senior secured facility, so cash goes to operations and debt service rather than shareholder distributions.

How does someone invest in URGN?

+

URGN ordinary shares trade on the Nasdaq Stock Market and can be bought through any US brokerage that offers Nasdaq-listed equities, including fractional shares at brokers that support them. The company is incorporated in Israel but files US domestic reports (10-K and 10-Q) with the SEC, so quarterly financials are available on EDGAR. The listed security is the ordinary share itself, not an ADR, so there is no depositary structure or fee to account for.

How has URGN stock performed in 2026?

+

As of the November 20, 2026 close near $31.68, UroGen shares were up about 40% year to date and about 28% over the past year, but down about 8% over the prior month and about 32% over three months, off a 52-week high of roughly $50.81 (the low was about $16.50). The shares fell after third-quarter results missed EPS estimates on November 4, 2026. Past performance does not predict future returns, and Walnut is not an investment adviser.

What is the IntraGel deal?

+

In August 2026 UroGen agreed to invest up to $7M in IntraGel Therapeutics' equity ($4M of it in the third quarter) and received a research license to IntraGel's SRGel biodegradable sustained-release gel, options for exclusive worldwide rights to up to three oncology products combining SRGel with UroGen-chosen compounds, and an option on TumoCure, a single-injection cisplatin gel for locally advanced head and neck cancer, exercisable after IntraGel completes a Phase 2 study. Option fees, milestones and royalties were not disclosed.

Has UroGen filed for approval of UGN-103?

+

Yes. UroGen submitted the new drug application for UGN-103 in August 2026, the FDA accepted it in October 2026, and the PDUFA target action date is June 14, 2027. UGN-103 uses the same mitomycin plus RTGel approach as Zusduri with simpler manufacturing, and showed 94.5% six-month duration of response in the Phase 3 UTOPIA trial; UroGen plans to submit 12-month data during the review.

How did UroGen do in its latest quarter?

+

In the third quarter of 2026, reported November 4, UroGen posted revenue of ~$89.0M, ahead of revenue estimates and up from ~$27.5M a year earlier, with Zusduri at ~$68.0M and Jelmyto at ~$21.0M. Operating income was ~$8.3M, but the net loss of ~$1.5M ($0.03 per share) missed the ~$0.11 profit analysts expected, and Jelmyto 2026 guidance was cut to about $90M. The shares fell on the report.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with UroGen Pharma Ltd.'s investor relations page or your broker before making investment decisions.